Free Trial

2seventy bio (TSVT) Competitors

2seventy bio logo
$4.97 +0.01 (+0.20%)
Closing price 04:00 PM Eastern
Extended Trading
$4.97 0.00 (0.00%)
As of 06:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TSVT vs. BGM, OCUL, IOVA, SNDX, WVE, COLL, ELVN, DYN, GPCR, and ETNB

Should you be buying 2seventy bio stock or one of its competitors? The main competitors of 2seventy bio include Qilian International Holding Group (BGM), Ocular Therapeutix (OCUL), Iovance Biotherapeutics (IOVA), Syndax Pharmaceuticals (SNDX), Wave Life Sciences (WVE), Collegium Pharmaceutical (COLL), Enliven Therapeutics (ELVN), Dyne Therapeutics (DYN), Structure Therapeutics (GPCR), and 89bio (ETNB). These companies are all part of the "pharmaceutical products" industry.

2seventy bio vs.

2seventy bio (NASDAQ:TSVT) and Qilian International Holding Group (NASDAQ:BGM) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their community ranking, dividends, earnings, media sentiment, analyst recommendations, institutional ownership, profitability, valuation and risk.

Qilian International Holding Group has a net margin of 0.00% compared to 2seventy bio's net margin of -207.25%. Qilian International Holding Group's return on equity of 0.00% beat 2seventy bio's return on equity.

Company Net Margins Return on Equity Return on Assets
2seventy bio-207.25% -53.65% -23.67%
Qilian International Holding Group N/A N/A N/A

Qilian International Holding Group has lower revenue, but higher earnings than 2seventy bio.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
2seventy bio$37.86M6.87-$217.57M-$1.12-4.44
Qilian International Holding Group$25.10M40.64-$1.44MN/AN/A

2seventy bio has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500. Comparatively, Qilian International Holding Group has a beta of 1.32, indicating that its stock price is 32% more volatile than the S&P 500.

93.9% of 2seventy bio shares are held by institutional investors. 7.2% of 2seventy bio shares are held by insiders. Comparatively, 58.7% of Qilian International Holding Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

2seventy bio received 25 more outperform votes than Qilian International Holding Group when rated by MarketBeat users.

CompanyUnderperformOutperform
2seventy bioOutperform Votes
25
46.30%
Underperform Votes
29
53.70%
Qilian International Holding GroupN/AN/A

2seventy bio currently has a consensus target price of $5.60, suggesting a potential upside of 12.68%. Given 2seventy bio's stronger consensus rating and higher possible upside, equities research analysts plainly believe 2seventy bio is more favorable than Qilian International Holding Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
2seventy bio
1 Sell rating(s)
4 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.29
Qilian International Holding Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, 2seventy bio had 4 more articles in the media than Qilian International Holding Group. MarketBeat recorded 5 mentions for 2seventy bio and 1 mentions for Qilian International Holding Group. Qilian International Holding Group's average media sentiment score of 1.87 beat 2seventy bio's score of 0.58 indicating that Qilian International Holding Group is being referred to more favorably in the news media.

Company Overall Sentiment
2seventy bio Positive
Qilian International Holding Group Very Positive

Summary

2seventy bio and Qilian International Holding Group tied by winning 8 of the 16 factors compared between the two stocks.

Remove Ads
Get 2seventy bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for TSVT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TSVT vs. The Competition

Metric2seventy bioPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$260.12M$6.32B$5.33B$7.57B
Dividend YieldN/A3.23%5.11%4.33%
P/E Ratio-2.676.7921.7317.81
Price / Sales6.87225.93379.1494.58
Price / CashN/A65.6738.1534.64
Price / Book0.995.866.464.00
Net Income-$217.57M$141.86M$3.20B$247.23M
7 Day Performance1.64%8.98%6.54%7.26%
1 Month Performance0.40%-12.65%-8.55%-6.26%
1 Year Performance-0.30%-11.99%10.33%-0.18%

2seventy bio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TSVT
2seventy bio
2.0477 of 5 stars
$4.97
+0.2%
$5.60
+12.7%
-1.6%$260.12M$37.86M-2.67440Short Interest ↓
Positive News
BGM
Qilian International Holding Group
N/A$10.62
-0.9%
N/AN/A$1.03B$25.10M0.00298Positive News
OCUL
Ocular Therapeutix
3.4113 of 5 stars
$6.30
-0.9%
$16.38
+159.9%
-5.3%$1.00B$63.72M-4.77230Gap Down
IOVA
Iovance Biotherapeutics
4.2578 of 5 stars
$3.03
+1.0%
$20.25
+568.3%
-72.4%$993.47M$164.07M-2.03500Analyst Forecast
News Coverage
High Trading Volume
SNDX
Syndax Pharmaceuticals
3.4858 of 5 stars
$11.01
-2.1%
$36.20
+228.8%
-48.3%$947.34M$23.68M-3.03110Gap Down
WVE
Wave Life Sciences
4.1802 of 5 stars
$5.80
-3.8%
$22.60
+289.7%
+3.4%$890.22M$108.30M-5.23240Short Interest ↑
Analyst Revision
COLL
Collegium Pharmaceutical
4.1648 of 5 stars
$27.38
-2.7%
$43.60
+59.2%
-25.1%$879.77M$631.45M11.80210News Coverage
Positive News
Gap Down
ELVN
Enliven Therapeutics
2.5509 of 5 stars
$17.87
-4.4%
$38.75
+116.8%
-18.5%$875.70MN/A-9.4150News Coverage
DYN
Dyne Therapeutics
3.73 of 5 stars
$7.49
-9.5%
$47.46
+533.7%
-71.1%$847.28MN/A-2.10100Positive News
GPCR
Structure Therapeutics
2.5699 of 5 stars
$14.31
-5.4%
$81.29
+468.0%
-51.8%$820.58MN/A-19.34136News Coverage
ETNB
89bio
2.5806 of 5 stars
$5.49
-4.9%
$27.56
+401.9%
-39.7%$801.45MN/A-1.8940Short Interest ↑
News Coverage
Gap Down
High Trading Volume
Remove Ads

Related Companies and Tools


This page (NASDAQ:TSVT) was last updated on 4/15/2025 by MarketBeat.com Staff
From Our Partners